The 16 year-old Oxford Nanopore provides pocketable kits to analyse RNA/DNA samples and supplies coronavirus testing kits to the NHS.
The company is expected to be valued at £3 billion in the LSE IPO when it aims to raise £300 million.
“Ever since we founded Oxford Nanopore, we have been driven by making science more accessible, towards our goal of enabling the analysis of anything, by anyone, anywhere,” says Oxford Nanopore founding CEO Gordon Sanghera, “
we believe Oxford Nanopore is ideally suited to both disrupt existing markets and create entirely new ones. An IPO will be a step on the journey to make our vision a reality, supporting our ambitious growth plans and enhancing our ability to innovate and grow.”